Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized Antithrombotic Therapy in Stroke Prevention
NCT03471169Phase 1Unknown
- Sponsor
- Xuanwu Hospital
- Start
- Apr 2017
- Primary completion
- Dec 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of aspirin, clopidogrel and cilostazol in ischemic stroke and cerebrovascular disease (2 arms), sponsored by Xuanwu Hospital. Primary endpoint: Aspirin Efficacy at 1 year. Status: unknown.
02
Drugs
aspirinclopidogrelcilostazol
03
Conditions
ischemic strokecerebrovascular disease
Beyond the preview
Go deeper on NCT03471169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03471169.